• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Transphorm Announces Fiscal 2024 First Quarter Results and Provides Business Update

    8/14/23 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology
    Get the next $TGAN alert in real time by email

    Transphorm Reports First Quarter Revenue of $5.9 Million, Representing 14% Year-Over-Year Growth

    Fiscal First Quarter Gross Margin Increased to 36%, a Substantial Sequential Increase from 5% in the Prior Quarter

    Company to Host Webcast Today at 5:00 p.m. EDT to Review Quarterly Results and Provide a Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today financial results for its fiscal 2024 first quarter ended June 30, 2023.

    Corporate Updates

    • Raised $7.94 million in gross proceeds in the second fiscal quarter through the completion of the previously announced rights offering.
    • With the rights offering completed, we are now beginning our previously announced strategic review of Transphorm with the goal of maximizing shareholder value, encompassing potential strategic and/or traditional equity or debt financing, US and Asia-based licensing opportunities, and M&A opportunities.

    Key Business Highlights

    • Reported revenue of $5.9 million for the first quarter of fiscal 2024 with roughly an equal split in Product revenue and Government revenue, a 14% increase over the first quarter of fiscal 2023.
    • Gross margin in the quarter was 36%, a significant increase from the 5% delivered in the prior quarter, representing an increase of 3100 basis points.
    • Continued to grow its 5-year pipeline opportunity—now at over $450 million, up 3% from the Company's previous update in June 2023. With traction in design-ins and opportunities nearing production, the Company expects to resume sequential product revenue growth in the second quarter of fiscal 2024.
    • Secured and now successfully performing on the $15 million National Security Technology Accelerator (NSTXL) contract, recognizing revenue of $2.9 million during the first quarter of fiscal 2024 and cash collections of $2.9 million subsequent to quarter end.
    • Continued capacity increases with record monthly epiwafer output achieved from the Company's epiwafer operations in Japan, and released two additional reactors for process development at GlobalWafers' epiwafer operations.

    High Power Segment Update – Continued Leadership of Transphorm in GaN

    • Increased total design-ins for higher power (300 Watt – 7.5 Kilowatt) to over 75 (with over 30 in production), an increase in ongoing design-ins of 25% from the Company's previous update in June 2023, with traction in segments like micro-inverter and computing.
    • Multiple 1.5-7.5 kilowatt range Titanium-rated power supplies with Transphorm GaN in production validating opportunities in AI Computing and Datacenter Power, enabling higher efficiencies and higher power densities, from power gaming graphics cards to datacenter PSUs, with fundamental patents for the underlying GaN topology.
    • Achieved industry milestone demonstrating up to 5 microsecond short circuit withstand time (SCWT) with a patented approach, and in collaboration with Yaskawa Electric Corporation, proving Transphorm's ability to meet the required SCWT capabilities of rugged power inverters such as servo motors, industrial motors, and electric vehicle powertrains served traditionally by silicon IGBTs or silicon carbide (SiC) MOSFETs, a GaN TAM of over $3 billion.
    • Working on multiple 300 Watt to 2 kilowatt charger platforms at leading Asia-based electric 2- and 3-wheeler companies, including a top-3 market leader company in India.
    • Demonstrated 600 Watt battery charging solution with Super GaN FETs achieving over 1% efficiency gain (14% loss reduction) vs. Silicon Superjunction while reducing power device count by 25% in a smaller GaN device versus a Silicon device – cheaper than Silicon, with higher performance.
    • Strengthened position in automotive EV market with 1200 V FET advancements: simulation model released and receiving interest from both tier 1 automotive OEMs and ODMs.

    Low Power Segment Update – Transphorm Enables Superior Performance

    • Increased total design-ins for power adapters and fast chargers (< 300 Watt) to over 100 (with over 30 in production), an increase in ongoing design-ins of 10% from the Company's previous update in June 2023.
    • Multiple notebook charger designs, including inbox wins now shipping for several of the top 5 OEMs, with production at tier 1 ODMs.
    • Successful traction with the Company's SiP strategy with versatility in using the same Transphorm FET for 65 Watt and 100 Watt adapter design, a crossover not competitively possible with e-mode GaN.
    • Secured a SiP based design win expected to ramp to multi-million units annually starting in the second half of fiscal 2024, at leading OEMs supplying diversified consumer power accessory products.

    "The design-ins and design wins of the past few quarters have set the stage for a return to sequential product revenue growth in the second fiscal quarter. Our differentiated and highly patented products/platforms for the high-power segments are gaining momentum in key targeted market areas – Computing, Energy & Industrial and EVs. Additionally, the net proceeds from our rights offering, together with an anticipated non-dilutive debt financing, will enable us to continue to execute on our long-term growth plans and, along with the strategic review process, allow for enhancing and maximizing shareholder value," commented Transphorm's President, CEO and Co-Founder, Primit Parikh.

    Cameron McAulay, CFO of Transphorm, stated, "We look forward to returning to sequential product revenue growth in the second fiscal quarter. A combination of our wins in the market, our pipeline and our strengthened balance sheet all will enable us to maximize growth in the future."

    Fiscal 2024 First Quarter Financial Results

    Revenue increased $0.7 million, or 14.1%, to $5.9 million for the three months ended June 30, 2023 from $5.2 million for the same period in 2022. Government contract revenue was up $2.2 million year-over-year.

    Operating expenses on a GAAP basis were $8.9 million in the first quarter of fiscal 2024, compared to $8.5 million in the fourth quarter of fiscal 2023 and $6.1 million in the first quarter of fiscal 2023. First quarter of fiscal 2024 operating expenses consisted of R&D expenses of $2.9 million and SG&A expenses of $6.0 million. Operating expenses on a non-GAAP basis were $6.8 million in the first quarter of fiscal 2024, a reduction from $7.5 million from the fourth quarter of fiscal 2023, and an increase from $5.4 million from the first quarter of fiscal 2023.

    GAAP net loss for the first quarter of fiscal 2024 was ($7.4) million, or ($0.22) per share, compared to GAAP net loss of ($8.8) million, or ($0.15) per share, in the prior quarter, and GAAP net loss of ($5.4) million, or ($0.10) per share, in the first quarter of fiscal 2023. On a non-GAAP basis, net loss for the first quarter of fiscal 2024 was ($4.5) million, or ($0.08) per share, compared to non-GAAP net loss of ($7.2) million, or ($0.13) per share, in the prior quarter, and non-GAAP net loss of ($4.2) million, or ($0.08) per share, in the first quarter of fiscal 2023.

    Cash, cash equivalents and restricted cash as of June 30, 2023, were $3.3 million, not including the net proceeds of $7.6 million from the recently concluded rights offering and $2.9 million of cash received from the execution of our Government program subsequent to quarter end.

    Conference Call and Webcast Information

    Event:

    Transphorm Fiscal 2024 First Quarter Financial Results

    Date:

    Monday, August 14, 2023

    Time:

    5:00 p.m. Eastern Daylight Time

    Webcast:

    https://edge.media-server.com/mmc/p/7m3qxbxn

    Conference Call:

    https://register.vevent.com/register/BI931ccd4bdc5a4d4a9056e740205da579

    A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company's website.

    About Transphorm

    Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry's leading JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company's vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm's innovations move power electronics beyond the limitations of silicon to achieve over 99% efficiency, 50% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa and WeChat @ Transphorm GaN.

    Non-GAAP Financial Measures

    This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm's ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm's results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization, change in fair value of promissory note and other income and expenses.

    A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company's expectations related to the asset-based debt financing initiatives it is pursuing, including the potential proceeds from such efforts; the Company's current expectation regarding its cash runway, without any additional financing; the expected date through which the Company's cash and any debt financing, if consummated, would fund the Company's operations; the expectation that the proceeds from the rights offering and debt financing initiatives will allow the Company to continue to execute on its long-term growth plans; the Company's 5-year pipeline and anticipated future growth; the Company's expectation that sequential product revenue growth will resume in the second quarter of fiscal 2024; the Company's expectations for future products, design-ins and market acceptance; and the information set forth in the quotes by the Company's management set forth herein. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: prevailing market conditions; whether the Company will be able to successfully close any debt financing; that any funds raised through the rights offering and any debt financing may not fund the Company's working capital requirements for as long as anticipated; that the Company's current forecasted cash runway, without any additional financing, may not last as long as anticipated; that the Company's anticipated strategic review may not result in any transaction (or that the terms of such transaction may not be favorable or acceptable to the Company or its stockholders); risks related to Transphorm's operations, such as additional financing requirements, access to capital and market acceptance of its current and future products; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company's filings with the Securities and Exchange Commission, including under the caption "Risk Factors" and elsewhere therein. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

    Transphorm, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands)

    (Unaudited)

     

     

    June 30, 2023

     

    March 31, 2023

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    3,311

     

     

    $

    15,527

     

    Restricted cash

     

    —

     

     

     

    500

     

    Accounts receivable

     

    6,915

     

     

     

    4,396

     

    Inventory

     

    8,885

     

     

     

    8,406

     

    Prepaid expenses and other current assets

     

    1,184

     

     

     

    1,859

     

    Total current assets

     

    20,295

     

     

     

    30,688

     

    Property and equipment, net

     

    7,957

     

     

     

    7,890

     

    Operating lease right-of-use assets

     

    2,863

     

     

     

    3,033

     

    Goodwill

     

    994

     

     

     

    1,079

     

    Intangible assets, net

     

    247

     

     

     

    321

     

    Investment in joint venture

     

    662

     

     

     

    715

     

    Other assets

     

    697

     

     

     

    726

     

    Total assets

    $

    33,715

     

     

    $

    44,452

     

     

     

     

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable and accrued expenses

    $

    6,517

     

     

    $

    7,895

     

    Accrued interest

     

    —

     

     

     

    180

     

    Accrued payroll and benefits

     

    1,228

     

     

     

    1,458

     

    Operating lease liabilities

     

    526

     

     

     

    404

     

    Revolving credit facility

     

    —

     

     

     

    12,000

     

    Total current liabilities

     

    8,271

     

     

     

    21,937

     

    Operating lease liabilities, net of current portion

     

    2,390

     

     

     

    2,670

     

    Other liabilities

     

    230

     

     

     

    230

     

    Total liabilities

     

    10,891

     

     

     

    24,837

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Preferred stock

     

    —

     

     

     

    —

     

    Common stock

     

    6

     

     

     

    6

     

    Additional paid-in capital

     

    247,027

     

     

     

    230,272

     

    Accumulated deficit

     

    (222,295

    )

     

     

    (209,236

    )

    Accumulated other comprehensive loss

     

    (1,914

    )

     

     

    (1,427

    )

    Total Stockholders' equity

     

    22,824

     

     

     

    19,615

     

    Total liabilities and stockholders' equity

    $

    33,715

     

     

    $

    44,452

     

    Transphorm, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands except share and per share data)

    (Unaudited)

     

     

    Three Months Ended

     

    June 30, 2023

    March 31, 2023

     

    June 30, 2022

    Revenue, net

    $

    5,883

     

    $

    3,192

     

     

    $

    5,156

     

    Cost of goods sold

     

    3,795

     

     

    3,017

     

     

     

    4,050

     

    Gross (loss) profit

     

    2,088

     

     

    175

     

     

     

    1,106

     

    Operating expenses:

     

     

     

     

    Research and development

     

    2,869

     

     

    3,013

     

     

     

    1,740

     

    Sales and marketing

     

    1,482

     

     

    1,651

     

     

     

    1,083

     

    General and administrative

     

    4,516

     

     

    3,854

     

     

     

    3,317

     

    Total operating expenses

     

    8,867

     

     

    8,518

     

     

     

    6,140

     

    Loss from operations

     

    (6,779

    )

     

    (8,343

    )

     

     

    (5,034

    )

    Interest expense

     

    8

     

     

    180

     

     

     

    182

     

    Loss in joint venture

     

    860

     

     

    659

     

     

     

    582

     

    Other income, net

     

    (200

    )

     

    (392

    )

     

     

    (445

    )

    Loss before tax expense

     

    (7,447

    )

     

    (8,790

    )

     

     

    (5,353

    )

    Tax expense

     

    —

     

     

    —

     

     

     

    —

     

    Net loss

    $

    (7,447

    )

    $

    (8,790

    )

     

    $

    (5,353

    )

     

     

     

     

     

    Deemed dividend related to warrant modification and issuance of Inducement warrants

     

    5,612

     

     

    —

     

     

     

    —

     

    Net loss attributable to common shareholders

    $

    (13,059

    )

    $

    (8,790

    )

     

    $

    (5,353

    )

     

     

     

     

     

    Net loss per share - basic and diluted

    $

    (0.22

    )

    $

    (0.15

    )

     

    $

    (0.10

    )

    Weighted average common shares outstanding - basic and diluted

     

    59,264,378

     

     

    57,144,218

     

     

     

    54,404,830

     

    Transphorm, Inc.

    Reconciliation of GAAP and Non-GAAP Financial Information (unaudited)

    (in thousands except per share data)

     

     

    Three Months Ended

     

    June 30, 2023

     

    March 31, 2023

     

    June 30, 2022

    GAAP net loss

    $

    (7,447

    )

     

    $

    (8,790

    )

     

    $

    (5,353

    )

    Adjustments:

     

     

     

     

     

    Stock-based compensation

     

    2,003

     

     

     

    858

     

     

     

    583

     

    Depreciation

     

    196

     

     

     

    174

     

     

     

    152

     

    Amortization

     

    74

     

     

     

    74

     

     

     

    74

     

    Total other expense, net

     

    668

     

     

     

    447

     

     

     

    319

     

    Total adjustments to GAAP net loss

     

    2,941

     

     

     

    1,553

     

     

     

    1,128

     

    Non-GAAP net loss

    $

    (4,506

    )

     

    $

    (7,237

    )

     

    $

    (4,225

    )

    GAAP net loss per share - basic and diluted

    $

    (0.22

    )

     

    $

    (0.15

    )

     

    $

    (0.10

    )

    Adjustment

     

    0.14

     

     

     

    0.02

     

     

     

    0.02

     

    Non-GAAP net loss per share - basic and diluted

    $

    (0.08

    )

     

    $

    (0.13

    )

     

    $

    (0.08

    )

    Weighted average common shares outstanding - basic and diluted

     

    59,264,378

     

     

     

    57,144,218

     

     

     

    54,404,830

     

     

    Three Months Ended

     

    June 30, 2023

     

    March 31, 2023

     

    June 30, 2022

    GAAP operating expenses

    $

    8,867

     

    $

    8,518

     

    $

    6,140

    Adjustments:

     

     

     

     

     

    Stock-based compensation

     

    1,865

     

     

     

    796

     

     

     

    543

     

    Depreciation

     

    99

     

     

     

    101

     

     

     

    95

     

    Amortization

     

    74

     

     

     

    74

     

     

     

    74

     

    Total adjustments to GAAP operating expenses

     

    2,038

     

     

     

    971

     

     

     

    712

     

    Non-GAAP operating expenses

    $

    6,829

     

     

    $

    7,547

     

     

    $

    5,428

     

    Transphorm, Inc.

    Condensed Consolidated Statements of Cash Flows (unaudited)

    (in thousands)

     

     

    Three Months Ended June 30,

     

    2023

     

    2022

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (7,447

    )

     

    $

    (5,353

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Provision for inventory

     

    2

     

     

     

    37

     

    Depreciation and amortization

     

    270

     

     

     

    226

     

    Amortization of right-of-use assets

     

    131

     

     

     

    150

     

    Stock-based compensation

     

    2,003

     

     

     

    583

     

    Interest cost

     

    —

     

     

     

    2

     

    Gain on sale of equipment

     

    (48

    )

     

     

    (100

    )

    Loss in joint venture

     

    860

     

     

     

    582

     

    Changes in fair value of derivative instruments

     

    124

     

     

     

    —

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (2,519

    )

     

     

    (645

    )

    Inventory

     

    (481

    )

     

     

    (670

    )

    Prepaid expenses and other current assets

     

    670

     

     

     

    (604

    )

    Other assets

     

    29

     

     

     

    (28

    )

    Accounts payable, accrued expenses, and other liabilities

     

    (2,017

    )

     

     

    1,086

     

    Deferred revenue

     

    —

     

     

     

    8

     

    Accrued payroll and benefits

     

    (230

    )

     

     

    (51

    )

    Operating lease liabilities

     

    (120

    )

     

     

    (136

    )

    Net cash used in operating activities

     

    (8,773

    )

     

     

    (4,913

    )

    Cash flows from investing activities:

     

     

     

    Purchases of property and equipment

     

    —

     

     

     

    (723

    )

    Proceeds from sale of equipment

     

    48

     

     

     

    100

     

    Investment in joint venture

     

    (807

    )

     

     

    (778

    )

    Net cash used in investing activities

     

    (759

    )

     

     

    (1,401

    )

    Cash flows from financing activities:

     

     

     

    Proceeds from stock option exercise

     

    —

     

     

     

    20

     

    Proceeds from issuance of common stock

     

    2,000

     

     

     

    16,000

     

    Cost associated with issuance of common stock

     

    (122

    )

     

     

    (280

    )

    Payment for taxes related to net share settlement of restricted stock units

     

    (1

    )

     

     

    —

     

    Proceeds from exercise of stock warrants

     

    7,263

     

     

     

    —

     

    Loan repayment

     

    (12,000

    )

     

     

    —

     

    Net cash provided by financing activities

     

    (2,860

    )

     

     

    15,740

     

    Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

     

    (324

    )

     

     

    (248

    )

    Net (decrease) increase in cash, cash equivalents and restricted cash

     

    (12,716

    )

     

     

    9,178

     

    Cash, cash equivalents and restricted cash at beginning of period

     

    16,027

     

     

     

    33,935

     

    Cash, cash equivalents and restricted cash at end of period

    $

    3,311

     

     

    $

    43,113

     

    Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets

     

     

     

    Cash and cash equivalents

    $

    3,311

     

     

    $

    42,613

     

    Restricted cash

     

    —

     

     

     

    500

     

    Cash, cash equivalents and restricted cash at end of period

    $

    3,311

     

     

    $

    43,113

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230814624919/en/

    Get the next $TGAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TGAN

    DatePrice TargetRatingAnalyst
    6/15/2022$9.00 → $6.50Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $TGAN
    SEC Filings

    View All

    SEC Form 15-12G filed by Transphorm Inc.

    15-12G - Transphorm, Inc. (0001715768) (Filer)

    7/1/24 9:01:49 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:13 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:04 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Transphorm downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Transphorm from Buy to Neutral and set a new price target of $6.50 from $9.00 previously

    6/15/22 7:40:43 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Phorm Investors L.P. sold $124,501,037 worth of shares (24,411,968 units at $5.10) (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:30:24 PM ET
    $TGAN
    Semiconductors
    Technology

    PRESIDENT AND CEO Parikh Primit returned 489,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:22 PM ET
    $TGAN
    Semiconductors
    Technology

    Chief Financial Officer Mcaulay Cameron returned 182,048 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:17 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Efinix Appoints Cameron McAulay as Chief Financial Officer

    McAulay Brings a Decade of Public-Company Semiconductor CFO Experience to Support Efinix's Global Expansion Efinix, Inc., the FPGA pioneer accelerating edge AI innovation, today announced the appointment of Cameron McAulay as Chief Financial Officer and Senior Vice President Finance. McAulay brings more than 20 years of financial leadership experience in the semiconductor and technology industries, including over a decade of service as CFO at publicly traded companies, making him uniquely qualified to help guide Efinix through its next stage of growth and value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303081

    3/3/26 11:00:00 AM ET
    $IVAC
    $TGAN
    Industrial Machinery/Components
    Technology
    Semiconductors

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Demonstrates a Bidirectional SuperGaN Power Supply with New Reference Design for E-Mobility and Energy/Industrial Markets

    300 W DC-to-DC Battery Charger Board Showcases Key Capability of GaN Technology Necessary to Advance E-Mobility Applications Transphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, today announced the release of a new 300 W DC-to-DC GaN reference design for 2- and 3-wheeled electric vehicle battery chargers. The TDDCDC-TPH-IN-BI-LLC-300W-RD design uses TP65H150G4PS 150 mOhm SuperGaN® FETs in a robust TO-220 package to power a high performing, high efficiency energy harvesting and distribution battery charging system. The new board notably demonstrates one of the most anticipated value propositions of a GaN power supply: bidirectionality. This capability indic

    6/11/24 3:00:00 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Leadership Updates

    Live Leadership Updates

    View All

    Efinix Appoints Cameron McAulay as Chief Financial Officer

    McAulay Brings a Decade of Public-Company Semiconductor CFO Experience to Support Efinix's Global Expansion Efinix, Inc., the FPGA pioneer accelerating edge AI innovation, today announced the appointment of Cameron McAulay as Chief Financial Officer and Senior Vice President Finance. McAulay brings more than 20 years of financial leadership experience in the semiconductor and technology industries, including over a decade of service as CFO at publicly traded companies, making him uniquely qualified to help guide Efinix through its next stage of growth and value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303081

    3/3/26 11:00:00 AM ET
    $IVAC
    $TGAN
    Industrial Machinery/Components
    Technology
    Semiconductors

    Transphorm Announces Appointment of Company Co-founders as Chief Executive Officer and Board Chair

    Follows Retirement of CEO and as part of the Company's Planned Succession Strategy Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced that its Board of Directors has appointed Dr. Primit Parikh as President and Chief Executive Officer of the Company and as a member of the Board. The Board also appointed Dr. Umesh Mishra to serve as Chair of the Board. Both of these appointments are effective May 15, 2023. Dr. Parikh and Dr. Mishra, who co-founded the Company's main operating subsidiary Transphorm Technology Inc., succeed Mario Rivas, who has served as the Company's Chief Executi

    5/15/23 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Appoints Six Company Leaders

    Company Veterans and Industry Leaders to Drive Next Phase of Growth Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and a global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—announced today the appointment of six company leaders. The roles are being filled by company veterans as well as newly hired experts, strategically building out Transphorm's executive bench. The collective sales, operations, engineering, and product marketing skillsets brought by these individuals will contribute to Transphorm's business growth and customer support strategies as the company responds to a rapidly rising demand for high voltage GaN power semiconductors acros

    10/27/22 9:00:00 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Transphorm Inc.

    SC 13D/A - Transphorm, Inc. (0001715768) (Subject)

    6/20/24 4:30:51 PM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/14/24 10:15:50 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/13/24 1:41:50 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Financials

    Live finance-specific insights

    View All

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Third Quarter Results and Provides Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the third quarter of its fiscal year ending March 31, 2024 ("Q3 Fiscal 2024"). On January 10, 2024, Transphorm announced that it entered into a definitive agreement to be acquired by a subsidiary of Renesas Electronics Corporation. The transaction values Transphorm at approximately $339 million. Key Business Highlights Reported total revenue of $4.7 million for Q3 Fiscal 2024, an increase of 4.0% over the same quarter last year and a decrease of 6.8% from the prior quarter. Product revenue was $3.2 million in the quarter, a decrease of 20%

    2/20/24 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Second Quarter Results and Provides Business Update

    - Reports Second Quarter Year-Over-Year Revenue Grew 37% to $5.0 Million as Gross Margin Increased by 11.5% to 23% - Product Revenue Increased to $3.55 Million, Up 18% Over the Prior Quarter - Recently Engaged BofA Securities, Inc. to Act as Financial Advisor in Company's Strategic Review to Enhance Stockholder Value - Company to Host Webcast Today at 5:00 p.m. EST to Review Quarterly Results and Provide a Business Update Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the second quarter of its fiscal year ending March 31, 2024 ("Q2 Fiscal 2024"). Primit Parikh, Transphorm's CEO and Co-Fo

    11/9/23 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology